Clinical Trial Update: Study of a DNA Immunotherapy to Treat Melanoma [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/Phase 2 clinical trial of a DNA immunotherapy for malignant melanoma sponsored by Scancell Ltd has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• DNA immunotherapy

Snippet

Sponsor: Scancell Ltd | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: TERMINATED